Telmisartan市場：按成分、按適應症、按劑型、按分銷管道、按地區

預計2024年Telmisartan的全球市場規模為42億美元，預計2031年將達到54.1億美元，2024年至2031年的複合年成長率為3.7%。

圖：2024 年Telmisartan市場佔有率（%），依地區分類

Telmisartan是一種血管收縮素II 受體拮抗劑，主要用於治療高血壓和糖尿病腎臟病。它的作用是選擇性抑制血管收縮素II 與血管平滑肌和腎上腺中存在的 AT1 受體的結合。Telmisartan可透過抑制血管收縮素II的血管收縮和醛固酮分泌作用來降低血壓。Telmisartan以多種品牌作為口服藥物出售，其安全性已通過長期臨床試驗得到證實。人們對心血管健康意識的提高和高血壓盛行率的增加可能會推動全球Telmisartan市場的成長。

市場動態：

人口快速老化、全球高血壓盛行率上升、肥胖導致的久坐生活方式增加以及新興國家醫療保健支出增加等因素推動了Telmisartan的全球市場成長。然而，學名藥替代的潛力和主要品牌的專利到期可能會給市場相關人員帶來挑戰。擴大Telmisartan治療用途的持續研究以及評估其治療高血壓以外疾病功效的正在進行的臨床試驗可能會在不久的將來為相關人員提供機會。與開發中國家的當地分銷網路合作​​也是挖掘未滿足需求的一種有吸引力的方式。

本研究的主要特點

• 本報告對全球Telmisartan市場進行了詳細分析，並提出了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
• 它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
• 它包括基於公司亮點、產品系列、主要亮點、業績和策略等參數的全球Telmisartan市場主要企業的概況。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
• 全球Telmisartan市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 透過用於全球Telmisartan市場分析的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• 一致的機會地圖 (COM)

第3章 市場動態、法規與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管場景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球Telmisartan市場－冠狀病毒（COVID-19）大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球Telmisartan市場，依構成，2019-2031（十億美元）

• 介紹
• 單身的
• 混合物

第6章Telmisartan全球市場，依指標分類，2019-2031 年（十億美元）

• 介紹
• 高血壓
• 腎臟病
• 肝腎症候群
• 心臟麻痹
• 中風

第7章Telmisartan全球市場，按劑型，2019-2031（十億美元）

• 介紹
• 錠劑
• 膠囊
• 注射
• 口服混懸劑

第8章全球Telmisartan市場，依通路，2019-2031（十億美元）

• 介紹
• 醫院藥房
• 零售藥房
• 網路藥房

第9章2019-2031年全球Telmisartan市場（按地區）（十億美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第10章競爭格局

• 公司簡介
  • Boehringer Ingelheim GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan NV
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

第11章分析師建議

• 上升和下降
• 綜合機會圖

第12章參考文獻與調查方法

• 參考
• 調查方法

Global telmisartan market is estimated to be valued at USD 4.20 Bn in 2024 and is expected to reach USD 5.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.

Figure. Telmisartan Market Share (%), By Region 2024

Telmisartan is an angiotensin II receptor antagonist that is used primarily in the treatment of hypertension and diabetic nephropathy. It works by selectively blocking the binding of angiotensin II to the AT1 receptors present in vascular smooth muscle and the adrenal glands. By blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II, telmisartan helps lower blood pressure. It is available under various brand names as an oral medication and has a well-established safety profile supported by long-term clinical trials. Growing awareness about cardiovascular health and increasing prevalence of hypertension can drive the global telmisartan market growth.

Market Dynamics:

Global telmisartan market growth is driven by factors such as rapidly aging population, rising prevalence of hypertension worldwide, increasing adoption of sedentary lifestyle resulting in obesity, and growing healthcare expenditure in emerging nations. However, availability of generic substitutes and patent expiration of major brands can pose challenges for market players. Continuous research on expanding therapeutic applications of telmisartan and ongoing clinical trials evaluating its efficacy in treatment of conditions beyond hypertension can offer opportunities for stakeholders in the near future. Partnerships with local distribution networks in developing countries also provide an attractive avenue for leveraging unmet demand.

Key Features of the Study:

• This report provides in-depth analysis of the global telmisartan market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global telmisartan market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global telmisartan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global telmisartan market

Detailed Segmentation-

• By Composition
  • Single
  • Combinational
• By Indication
  • Hypertension
  • Nephropathy
  • Hepatorenal Syndrome
  • Cardiac Arrest
  • Stroke
• By Dosage Form
  • Tablets
  • Capsules
  • Injection
  • Oral suspension
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Boehringer Ingelheim GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Composition
  • Market Snapshot, By Indication
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Telmisartan Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Telmisartan Market, By Composition, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Single
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Combinational
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Telmisartan Market, By Indication 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hypertension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Nephropathy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Hepatorenal Syndrome
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cardiac Arrest
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Stroke
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Telmisartan Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Tablets
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Capsules
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oral suspension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Telmisartan Market, By Distribution Channel 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Telmisartan Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Boehringer Ingelheim GmbH
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark Pharmaceuticals Ltd.
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sandoz International GmbH
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact